persistent itch, skin lesions and poor sleep quality.7-13Itch is one of the most burdensome symptoms of both conditions, with 87% of patients with atopic dermatitis seeking freedom from itch, and 88% of those with prurigo nodularis rating it as their worst symptom.13,14






“These new data reinforce our understanding of nemolizumab’s rapid onset of action in relieving itch and, in turn, improving sleep in patients living with atopic dermatitis and prurigo nodularis, as well as its role in targeting the IL-31 pathway. We are proud to be driving innovation that directly addresses the most urgent needs of people living with chronic skin conditions and remain committed to delivering effective, fast-acting and lasting solutions.”

CHRISTOPHE PIKETTY, M.D., PH.D.

AUTHOR AND GLOBAL PROGRAM HEAD THERAPEUTIC DERMATOLOGY

GALDERMA






=*=*=*=*=*=
当前为第3/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页